Please login to the form below

Not currently logged in
Email:
Password:

enzastaurin

This page shows the latest enzastaurin news and features for those working in and with pharma, biotech and healthcare.

Lilly/Boehringer's empagliflozin faces US approval delay

Lilly/Boehringer's empagliflozin faces US approval delay

last year it suffered late-stage setbacks with antidepressant edivoxetine, enzastaurin for lymphoma and tabalumab for rheumatoid arthritis.

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics